Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Description

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

Conditions

Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II

Study Overview

Study Details

Study overview

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

New York

NYU Langone Health, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject signed inform consent
  • * Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
  • * Pre-operative criteria
  • * Lung nodule suspicious for NSCLC
  • * Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
  • * Clinical stage I or Clinical stage II
  • * Not pregnant or nursing
  • * Negative pregnancy test in premenopausal women
  • * Fertile patients must use effective contraception
  • * More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

CivaTech Oncology,

Abe Wu, MD, PRINCIPAL_INVESTIGATOR, MSKCC

Study Record Dates

2025-12